Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant Mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
The in vivo grade recombinant anti-human CD47 Mouse IgG1 Kappa monoclonal antibody was produced in mammalian cells.
Clone: B6H12.
Isotype: Mouse IgG1 Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: B6H12) specifically binds to human CD47.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD47 protein.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Shipping: The in vivo grade recombinant anti-human CD47 antibodies (clone of B6H12) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG1 isotype control antibody
Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma
Wang, Y., et al. Mol Ther. 2023 May 3;31(5):1321-1335. doi: 10.1016/j.ymthe.2023.03.012. PMID: 37171006
The anti-CD47 antibody B6H12 suppressed tumor cell growth, motility, and enhanced macrophage-mediated phagocytosis in IOMM-Lee meningioma cells in vitro. In vivo, B6H12 or MIAP301 significantly inhibited tumor growth in NSG mice, with effects partially blocked by macrophage depletion. Combination with dinutuximab and aNK cells enhanced neuroblastoma xenograft regression, as shown by wound healing and transwell invasion assays.
Tags: anti-human CD47 B6H12; anti-human CD47 B6H12 mAb
CD47 Blocking Antibody Enhances Biodegradable PLGA and Naked DNA Vaccine Induced T Cell Responses in a Murine Model of HPV16+ Tumor
Li, X., et al. Front Immunol. 2023 Apr 13;14:1163618. doi: 10.3389/fimmu.2023.1163618. PMID: 37075968
B6H12, administered intraperitoneally at 200 μg per mouse, enhanced immune responses in HPV16+ TC-1 tumor-bearing C57BL/6 mice. Combined with a PLGA-based DNA vaccine, it significantly increased CD8+ T cell infiltration and IFN-γ production in tumors, as measured by ELISPOT assays, with tumor volume monitored every 3 days using calipers.
Tags: anti-human CD47 B6H12 in vivo; anti-human CD47 B6H12 in animal model
A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
Liu, Y., et al. Oncotarget. 2016 Feb 29;7(9):10148-67. doi: 10.18632/oncotarget.7308. PMID: 26840086
The anti-CD47 antibody B6H12, administered at 10 mg/kg twice weekly via intraperitoneal injection, inhibited tumor growth in MDA-MB-231 triple-negative breast cancer xenografts in NSG mice by preventing SIRPα engagement. Immunohistochemistry confirmed reduced EGFR phosphorylation, indicating suppression of stem cell and EGF signaling.
Tags: anti-human CD47 B6H12 mAb in animal model; function of anti-human CD47 B6H12
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Sockolosky, J. T., et al. Nat Med. 2015 Oct;21(10):1126-33. doi: 10.1038/nm.3931. PMID: 26259518
In vivo administration of B6H12 at 250 μg per mouse every other day for 2 weeks led to significant tumor regression in C57BL/6 mice with B16F10 melanoma. Increased tumor-infiltrating CD8+ T cells were observed, with therapeutic effects abrogated by CD8+ T cell depletion, confirming T cell dependency.
Tags: anti-human CD47 B6H12; anti-CD47 clone B6H12
Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
Chao, M. P., et al. Cancer Res. 2010 Dec 15;70(24):10182-90. doi: 10.1158/0008-5472.CAN-10-2238. PMID: 21163924
B6H12, administered at 100 μg per mouse daily, significantly reduced leukemia burden in bone marrow of NOD/SCID mice engrafted with 1 × 10^6 primary ALL cells via tail vein. Flow cytometry confirmed depletion of CD47+ leukemic cells, and survival was significantly prolonged compared to controls.
Tags: bioactivity of anti-human CD47 B6H12; bioactivity of anti-human CD47 B6H12 mAb
For more references about anti-human CD47 antibody (B6H12), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf